Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (130,356)	$ (35,181)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	56,812	7,306
Non-cash interest expense	40,071	8,727
Change in fair value of derivative liabilities	1,025	7,499
Change in fair value of share-settled forward asset	8,956
Non-cash bonus expense	1,412	0
Depreciation and amortization	472	490
Non-cash lease expense	333	0
Paid-in-kind interest and accrued interest on repayment of 2022 Notes	(9,341)	0
Gain on extinguishment of debt	0	(2,515)
Other	0	(70)
Changes in operating assets and liabilities:
Accounts receivable	(175)	290
Inventory	(2,279)	446
Prepaid expenses and other current assets	(1,907)	166
Other long-term assets	(1)	(1,780)
Accounts payable	1,835	629
Accrued expenses	(61)	(222)
Accrued settlement liability	250
Other current liabilities	(452)	0
Other long-term liabilities	77	(251)
Net cash used in operating activities	(33,329)	(14,466)
Cash flows from investing activities
Purchases of property and equipment	(431)	(5)
Net cash used in investing activities	(431)	(5)
Cash flows from financing activities
Related party proceeds from PIPE financing	36,950	0
Proceeds from Business Combination and PIPE financing	13,414	0
Proceeds from draw down on GEM Agreement	9,900
Payments of offering costs	(8,188)	0
Repayment of 2022 Notes	(25,813)	0
Proceeds from exercise of stock options	58	74
Proceeds from exercise of common stock warrants	70	0
Proceeds from issuance of convertible notes	0	37,130
Proceeds from issuance of convertible notes to related parties	0	11,475
Net cash provided by financing activities	26,391	48,679
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(18)	(6)
Net increase (decrease) in cash, cash equivalents and restricted cash	(7,387)	34,202
Cash, cash equivalents and restricted cash at beginning of period	26,176	7,668
Cash, cash equivalents and restricted cash at end of period	18,789	41,870
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	9,326	236
Supplemental schedule of noncash investing and financing activities:
Conversion of redeemable convertible preferred stock to common stock	152,978	0
Conversion of 2023 Notes into equity	101,978	0
Issuance of common stock warrants	17,602	21,970
Assumption of net liabilities from Business Combination	15,956	0
Issuance of share-settled forward asset	10,027
Offering costs paid in common stock	9,531	0
GEM commitment fee	2,500	0
Fair value of debt derivative liabilities related to issuance of convertible notes	$ 0	$ 17,540